Compare Globus Medical Inc. Class A Common Stock (GMED) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Under Armour Inc Class A — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Under Armour Inc Class A trades at $4.65 (market cap $2.03B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 5× Under Armour Inc Class A's market cap, and Globus Medical Inc. Class A Common Stock is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Under Armour Inc Class A for 19 Days on average.
| GMED | UA | |
|---|---|---|
Market Cap | $10.25B | $2.03B |
Volume | 1,059,528 | 2,242,648 |
Sector | Health | Consumer Cyclical |
52-Week High | $96.82 | $7.88 |
52-Week Low | $58.33 | $3.96 |
Typical Hold Time | 0 Days | 19 Days |
Enterprise Value | $9.76B | $3.01B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
Under Armour (UA) trades at $4.76, down 0.63% on the day, with a bullish technical signal but negative profitability. Recent earnings show mixed quarterly beats and misses, with Q1 2026 missing expectations. The company reported a net loss of -$201.27M for 2025, with revenue declining to $4.9B in 2026. Cash flow remains negative, and the stock faces headwinds from softer consumer demand.
The outlook is cautious due to persistent revenue declines and negative margins, though a low P/S ratio of 0.4 may attract value investors. Key risks include execution challenges and competitive pressure. Analyst sentiment is mixed, with 39.71% buy ratings but significant hold recommendations reflecting uncertainty.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
